President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare ProfessionalsDiabetes Information & Resources
Clinical Research50-Year Medalist Study
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowGet InvolvedEventsTributes & Special OccasionsCorporate & Foundation EngagementLegacy GivingWays to GivePhilanthropy TeamPublications

Paul G. Arrigg, M.D.

Position

Ophthalmologist; Chief, Vitreo-Retinal Surgery

Specialty

Retina - Vitreous

Teaching
Appointment

Assistant Professor of Ophthalmology, Harvard Medical School

Medical School

Tufts University School of Medicine

Internship

New England Medical Center

Residency

New England Medical Center

Fellowship

BIDMC

Specialty
Training

Retina - Vitreous Fellowship

Certification

American Board of Ophthalmologists

Bio
Since joining the Beetham Eye Institute (BEI) in 1982, Dr. Arrigg has devoted his professional career to providing diabetes eye care with particular emphasis on vitreo-retinal disease and surgery.  Dr. Arrigg is currently an Associate Professor, Department of Ophthalmology, Harvard Medical School, and Chief of Vitreo-Retinal Surgery at the BEI.  As part of his clinical and surgical practice, Dr. Arrigg has access to the latest diagnostic and treatment modalities while performing approximately 150 vitrectomy surgeries per year and conducting multiple intravitreous injection clinics for diabetic macular edema , diabetic retinopathy and macula degeneration.  Dr. Arrigg is a co-investigator for Diabetic Retinopathy Clinical Research Network (DRCR.net) studies conducted at the BEI and he has been an active participant in numerous federally funded and privatedly funded clinical research studies and trials, including the Diabetes Control and Complication Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study and numerous trials conducted at the Dana Farber Cancer Institute.

Paul G. Arrigg, M.D.